{"schema_version":"secwatch.filing_event.v1","accession":"0001447362-24-000121","form_type":"8-K","ticker":"CSTL","cik":"0001447362","company_name":"CASTLE BIOSCIENCES INC","filed_at":"2024-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.094354+00:00","generated_at":"2026-05-31T13:03:42.682634+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Castle Biosciences Q2 revenue jumps 74% to $87M; raises FY2024 guidance to $275-300M","bullets":["Revenue $87.0M (+74% YoY); net income $8.9M vs loss of $18.8M in Q2 2023.","Total test reports 25,102 (+49% YoY); TissueCypher +230%, DecisionDx-SCC +60%.","Raises FY2024 revenue guidance to $275-300M from prior $255-265M.","Adjusted EBITDA $21.5M vs ($5.3M) in Q2 2023; gross margin 81%.","Cash and investments $259.7M; net cash from operations $24.0M."],"urls":{"canonical":"https://secwatch.observer/filing/0001447362-24-000121","json":"https://secwatch.observer/filing/0001447362-24-000121.json","markdown":"https://secwatch.observer/filing/0001447362-24-000121.md","text":"https://secwatch.observer/filing/0001447362-24-000121.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447362/000144736224000121/0001447362-24-000121-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447362/000144736224000121/cstl-20240805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:03:42.682634+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}